BR112022003165A2 - Método de tratamento de cânceres associados a kras - Google Patents
Método de tratamento de cânceres associados a krasInfo
- Publication number
- BR112022003165A2 BR112022003165A2 BR112022003165A BR112022003165A BR112022003165A2 BR 112022003165 A2 BR112022003165 A2 BR 112022003165A2 BR 112022003165 A BR112022003165 A BR 112022003165A BR 112022003165 A BR112022003165 A BR 112022003165A BR 112022003165 A2 BR112022003165 A2 BR 112022003165A2
- Authority
- BR
- Brazil
- Prior art keywords
- kras
- associated cancers
- treating
- treating kras
- mutation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962890119P | 2019-08-22 | 2019-08-22 | |
| PCT/US2020/047090 WO2021034992A1 (en) | 2019-08-22 | 2020-08-20 | Method of treating kras-associated cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003165A2 true BR112022003165A2 (pt) | 2022-05-17 |
Family
ID=74660044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003165A BR112022003165A2 (pt) | 2019-08-22 | 2020-08-20 | Método de tratamento de cânceres associados a kras |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220273643A1 (https=) |
| EP (1) | EP4017489B1 (https=) |
| JP (1) | JP7602272B2 (https=) |
| KR (1) | KR20220050143A (https=) |
| CN (2) | CN119454706A (https=) |
| AU (1) | AU2020334069B2 (https=) |
| BR (1) | BR112022003165A2 (https=) |
| CA (1) | CA3150759A1 (https=) |
| IL (1) | IL290454B2 (https=) |
| MX (1) | MX2022002108A (https=) |
| WO (1) | WO2021034992A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CA3214172A1 (en) * | 2021-04-02 | 2022-10-06 | Mukesh K. Nyati | Combination therapy for cancer treatment |
| WO2023003417A1 (ko) * | 2021-07-22 | 2023-01-26 | 국립암센터 | Kras 돌연변이 특이적 저해제 및 이를 포함하는 암 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| CA2612183C (en) * | 2005-06-28 | 2015-08-11 | Genentech, Inc. | Egfr and kras mutations |
| WO2010114922A1 (en) * | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| WO2012064642A1 (en) * | 2010-11-08 | 2012-05-18 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| US20140256767A1 (en) | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| WO2014176475A2 (en) | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| EP3755323A4 (en) * | 2018-02-23 | 2021-11-24 | The Regents Of The University Of Michigan | EGFR DIMER DISRUPTORS AND THEIR USES |
-
2020
- 2020-08-20 MX MX2022002108A patent/MX2022002108A/es unknown
- 2020-08-20 CA CA3150759A patent/CA3150759A1/en active Pending
- 2020-08-20 JP JP2022511096A patent/JP7602272B2/ja active Active
- 2020-08-20 AU AU2020334069A patent/AU2020334069B2/en active Active
- 2020-08-20 EP EP20854314.0A patent/EP4017489B1/en active Active
- 2020-08-20 IL IL290454A patent/IL290454B2/en unknown
- 2020-08-20 WO PCT/US2020/047090 patent/WO2021034992A1/en not_active Ceased
- 2020-08-20 BR BR112022003165A patent/BR112022003165A2/pt unknown
- 2020-08-20 US US17/634,265 patent/US20220273643A1/en not_active Abandoned
- 2020-08-20 CN CN202411400491.9A patent/CN119454706A/zh active Pending
- 2020-08-20 CN CN202080059528.XA patent/CN114286676A/zh active Pending
- 2020-08-20 KR KR1020227007201A patent/KR20220050143A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021034992A1 (en) | 2021-02-25 |
| AU2020334069A1 (en) | 2022-03-24 |
| IL290454B2 (en) | 2025-12-01 |
| CN114286676A (zh) | 2022-04-05 |
| EP4017489B1 (en) | 2025-05-07 |
| JP2022545005A (ja) | 2022-10-24 |
| AU2020334069B2 (en) | 2026-02-19 |
| IL290454A (en) | 2022-04-01 |
| JP7602272B2 (ja) | 2024-12-18 |
| CN119454706A (zh) | 2025-02-18 |
| KR20220050143A (ko) | 2022-04-22 |
| CA3150759A1 (en) | 2021-02-25 |
| IL290454B1 (en) | 2025-08-01 |
| EP4017489A4 (en) | 2023-08-23 |
| EP4017489C0 (en) | 2025-05-07 |
| US20220273643A1 (en) | 2022-09-01 |
| MX2022002108A (es) | 2022-03-17 |
| EP4017489A1 (en) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003165A2 (pt) | Método de tratamento de cânceres associados a kras | |
| ZA202110422B (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| CL2022001731A1 (es) | Inhibidores de egfr. | |
| MX2024000230A (es) | Inhibidores de cdk2. | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| MX2025008593A (es) | Inhibidores de cdk | |
| MX385562B (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2. | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| EA201270752A1 (ru) | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| CR20240014A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| WO2022240971A3 (en) | Kras g12d inhibitors and uses thereof | |
| PH12021552579A1 (en) | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2022007626A (es) | Combinaciones. | |
| CO2022007910A2 (es) | Tratamientos contra el cáncer dirigidos a las células madre cancerosas | |
| EP4328319A3 (en) | Methods and compositions for identifying and treating patients with small cell lung cancer | |
| MX2025012153A (es) | Inhibidores de cdk2 | |
| PH12017501882A1 (en) | Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |